VP, Global Medical Lead Rare Cardiology (Secondment - 12 Months)

Pfizer•New York City, NY

4d•Hybrid

About The Position

WHY PATIENTS NEED YOU The Vice President, Global Medical Lead Rare Cardiology is accountable for defining and executing the global medical strategy for Pfizer’s rare cardiology portfolio, with primary responsibility for ATTR cardiomyopathy (ATTR‑CM) and future rare cardiovascular assets. This role provides enterprise‑level medical leadership across the full lifecycle ensuring that medical strategy is scientifically robust, patient‑centric, and aligned with Pfizer’s long‑term disease leadership ambitions. This ability to anticipate change, navigate increasing competition, and continuously adapt medical strategy, while maintaining scientific rigor, patient‑centricity, and long‑term disease leadership is required. WHAT YOU WILL ACHIEVE The Team Lead will serve as a senior medical partner to Regulatory, HEOR, Commercial, and Market Access, Safety while leading high‑impact external engagement with regulators, scientific leaders, and healthcare systems globally. Will be the strategic external scientific face and internal point person of our cardiology department, advocating Pfizer as leader partner, supporting the evidence generation and scientific excellence by overseeing global evidence‑generation strategy, including, clinical and post‑approval evidence, real‑world evidence and patient‑centric data and Investigator‑initiated research and medical grants. Will ensure high‑quality scientific communications, including publications, congress strategy, and advisory boards. Translate evidence into actionable insights for clinicians, regulators, and payers. Will lead and develop high‑performing global medical teams, foster a culture of scientific rigor, accountability, inclusion, and talent development. Will influence effectively complex, matrixed global organizations and serve as a role model for Pfizer Leadership Capabilities. The Global Medical Lead will need to show high level of scientific expertise in cardiology and rare disease and will benefit from an established and strong network of international KOLs in order to function as a peer and leader for medical affairs in developing this ambition. A key element of the work will be to continuously develop the medical strategy for the rare cardiology life cycle in a very rapid changing landscape and in close collaboration International and US stakeholders and various cross functional partners. Collaboration across functions, solution-orientation and leadership skills are key criteria for a successful candidate while showing strong ability to prioritize and focus strategies based on specific area requirements. HOW YOU WILL ACHIEVE IT Global Medical Strategy & Disease Leadership Define and lead the global medical strategy for rare cardiology on ATTR ‑ CM. Drive a disease ‑ centric approach, integrating biology, diagnostics, treatment pathways, and long ‑ term outcomes. Ensuring medical strategy supports sustained disease leadership, not only near ‑ term success. Deliver impact amid shifting standards of care, emerging competitors, and evolving healthcare system expectations while maintaining scientific rigor, patient‑centricity, and long‑term disease leadership. Able to develop the appropriate medical strategy regarding a dynamic and increasingly competitive environment. Anticipate scientific, clinical, and competitive shifts, translating them into proactive medical strategies. Ensure medical positioning evolves in line with emerging data, new entrants, and changing treatment paradigms. Own and define the global evidence ‑ generation vision for Rare Cardiology, ensuring data strategies anticipate future clinical, regulatory, and competitive needs, not only current requirements. Ensure evidence generation directly supports disease leadership, differentiation, and sustained relevance in an increasingly competitive environment. Translate evolving science, clinical practice, and competitive intelligence into proactive evidence priorities, adapting data plans as standards of care and treatment paradigms evolve. Ensure high ‑ quality scientific communications, including publications, congress strategy, and advisory boards. Translate evidence into actionable insights for clinicians, regulators, and payers. Maintain a clear medical narrative that shape clinical practice and policy. Additional responsibilities Actively participate in cross‑functional Teams supporting business development initiatives in cardiology, including early‑stage asset evaluation, licensing, partnership, or acquisition assessments, pipeline prioritization and portfolio shaping. Provide senior medical leadership and disease expertise to inform scientific and clinical differentiation, unmet medical need and patient impact and evidence gaps, Act as senior medical partner to Global Regulatory Affairs, contributing to regulatory requests, health authority interactions. People Leadership Actively drive succession planning and talent pipeline development for critical roles, ensuring continuity and long ‑ term organizational resilience. Identify, develop, and retain high ‑ potential talent, creating opportunities for growth, stretch assignments, and cross ‑ functional exposure. Lead and develop high ‑ performing global medical teams. Foster a culture of scientific rigor, accountability, inclusion, and talent development. External Engagement & Reputation Establish and sustain strategic partnerships with key external experts, professional societies, and patient advocacy organizations to shape disease understanding, scientific priorities, and long ‑ term medical positioning. Cross-Functional Collaboration Lead GMT and partner with International Medical, Regulatory, Legal and Commercial teams to ensure alignment of scientific strategy. Compliance & Governance Ensure all activities adhere to internal policies, industry standards, and regulatory requirements. Maintain high ethical standards in all scientific communications.

Requirements

BA/BS with 15+ years of experience.
Comfort operating in mechanism‑driven, cross‑indication strategies .
Experience in Medical Affairs or Clinical Development, preferably in Rare Disease.
Above country experience /(global or international) required.
Proven track record in pipeline strategy, evidence generation, and external engagement.
Strong understanding of global regulatory and compliance frameworks.
Ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.
Proven track record on critical clinical decision making, commercial and regulatory implications of clinical study design elements, analysis of complex scientific data required.
Proven track record of ability to work and partner successfully with cross-functional colleagues in a matrix team setting across countries and internationally with diverse colleagues and cultures.
Excellent communication, leadership, and matrix management skills.
Candidate demonstrates a breadth of diverse leadership experiences and capabilities including:
Track record of evidence generation required.
Demonstrated executional capabilities and leadership without authority in prior medical affairs roles.
Ability to influence and lead in a complex, global environment.
Strong collaboration and stakeholder management skills.
Passion for innovation and improving patient outcomes.

Nice To Haves

MBA/MS with 13+ years of experience; OR PhD or JD with 10+ years of experience; OR MD/DVM with 9+ years of experience.

Responsibilities

Define and lead the global medical strategy for rare cardiology on ATTR ‑ CM.
Drive a disease ‑ centric approach, integrating biology, diagnostics, treatment pathways, and long ‑ term outcomes.
Deliver impact amid shifting standards of care, emerging competitors, and evolving healthcare system expectations while maintaining scientific rigor, patient‑centricity, and long‑term disease leadership.
Anticipate scientific, clinical, and competitive shifts, translating them into proactive medical strategies.
Ensure medical positioning evolves in line with emerging data, new entrants, and changing treatment paradigms.
Own and define the global evidence ‑ generation vision for Rare Cardiology, ensuring data strategies anticipate future clinical, regulatory, and competitive needs, not only current requirements.
Translate evolving science, clinical practice, and competitive intelligence into proactive evidence priorities, adapting data plans as standards of care and treatment paradigms evolve.
Ensure high ‑ quality scientific communications, including publications, congress strategy, and advisory boards.
Translate evidence into actionable insights for clinicians, regulators, and payers.
Maintain a clear medical narrative that shape clinical practice and policy.
Actively participate in cross‑functional Teams supporting business development initiatives in cardiology, including early‑stage asset evaluation, licensing, partnership, or acquisition assessments, pipeline prioritization and portfolio shaping.
Provide senior medical leadership and disease expertise to inform scientific and clinical differentiation, unmet medical need and patient impact and evidence gaps
Act as senior medical partner to Global Regulatory Affairs, contributing to regulatory requests, health authority interactions.
Actively drive succession planning and talent pipeline development for critical roles, ensuring continuity and long ‑ term organizational resilience.
Identify, develop, and retain high ‑ potential talent, creating opportunities for growth, stretch assignments, and cross ‑ functional exposure.
Lead and develop high ‑ performing global medical teams.
Foster a culture of scientific rigor, accountability, inclusion, and talent development.
Establish and sustain strategic partnerships with key external experts, professional societies, and patient advocacy organizations to shape disease understanding, scientific priorities, and long ‑ term medical positioning.
Lead GMT and partner with International Medical, Regulatory, Legal and Commercial teams to ensure alignment of scientific strategy.
Ensure all activities adhere to internal policies, industry standards, and regulatory requirements.
Maintain high ethical standards in all scientific communications.